ইউরোপীয় ইউনিয়ন - ফিনিশ - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

ইউরোপীয় ইউনিয়ন - ফিনিশ - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

ইউরোপীয় ইউনিয়ন - ফিনিশ - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 käytettävissä olevista tiedoista eri yhdistelmistä).

ফিনল্যান্ড - ফিনিশ - Fimea (Suomen lääkevirasto)

krka, d.d., novo mesto - permethrin, imidacloprid - paikallisvaleluliuos - 2000 mg / 400 mg - permetriini

ফিনল্যান্ড - ফিনিশ - Fimea (Suomen lääkevirasto)

krka, d.d., novo mesto - permethrin, imidacloprid - paikallisvaleluliuos - 1250 mg / 250 mg - permetriini

ফিনল্যান্ড - ফিনিশ - Fimea (Suomen lääkevirasto)

krka, d.d., novo mesto - permethrin, imidacloprid - paikallisvaleluliuos - 500 mg / 100 mg - permetriini

ফিনল্যান্ড - ফিনিশ - Fimea (Suomen lääkevirasto)

krka, d.d., novo mesto - permethrin, imidacloprid - paikallisvaleluliuos - 200 mg / 40 mg - permetriini

ফিনল্যান্ড - ফিনিশ - Fimea (Suomen lääkevirasto)

viatris oy - orphenadrine citrate, paracetamol - tabletti - 35 mg / 450 mg - orfenadriini

ফিনল্যান্ড - ফিনিশ - Fimea (Suomen lääkevirasto)

orion corporation - paracetamol - tabletti - 500 mg - parasetamoli

ফিনল্যান্ড - ফিনিশ - Fimea (Suomen lääkevirasto)

sanofi oy - codeine phosphate hemihydrate, paracetamol - tabletti - kodeiini ja parasetamoli